A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03816163

Title field or adapter rule

{'original_value': 'A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.431663+00:00

Published At

2026-10-14T00:00:00+00:00

Record Updated At

2026-10-14

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-14", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03816163"

protocolSection.identificationModule.officialTitle

"A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Cancer (protocolSection.conditionsModule.conditions)
• Metastatic Pancreatic Cancer (protocolSection.conditionsModule.conditions)
• Metastatic Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['zolbetuximab +nab-paclitaxel + gemcitabine'], 'description': 'Administered as an intravenous infusion.', 'name': 'zolbetuximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['nab-paclitaxel + gemcitabine', 'zolbetuximab +nab-paclitaxel + gemcitabine'], 'description': 'Administered as an intravenous infusion', 'name': 'nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['nab-paclitaxel + gemcitabine', 'zolbetuximab +nab-paclitaxel + gemcitabine'], 'description': 'Administered as an intravenous infusion', 'name': 'gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• zolbetuximab (protocolSection.armsInterventionsModule.interventions[].name)
• nab-paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)
• gemcitabine (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.